Black Diamond Therapeutics, Inc. (BDTX) company profile
Close on Nov 13, 2026Market cap $84.46MP/E –Yield –
About Black Diamond Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Black Diamond Therapeutics is a clinical-stage oncology company that discovers and develops orally available, small molecule therapies for patients with genetically defined cancers. Using its proprietary MAP drug discovery platform, the company designs brain-penetrant MasterKey inhibitors that target shared oncogenic mutation families across multiple tumor types while minimizing toxicities. Its lead clinical product candidate is silevertinib, an irreversible EGFR MasterKey inhibitor evaluated in clinical trials for non-small cell lung cancer and glioblastoma. The company also developed BDTX-4933, a brain-penetrant RAF inhibitor whose worldwide development and commercialization rights are licensed to Servier, and is pursuing partnerships for its preclinical FGFR2/3 development program, BDTX-4876.
The company operates without internal manufacturing facilities, relying instead on third-party contract manufacturing organizations for preclinical, clinical, and planned commercial drug production. Black Diamond Therapeutics focuses its commercial strategy on the United States by preparing a specialized internal sales organization to reach treating oncologists, while intending to utilize third-party distributors internationally. The provided text does not state the company's headquarters location.
Summary of the business section of Black Diamond Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Black Diamond Therapeutics, Inc.
- Founded
- 2014
- Headquarters
- Cambridge, MA
- Address
- 245 First Street, 18th Floor 02142
- Phone
- (617) 417-5868
- Website
- blackdiamondtherapeutics.com
- Employees
- 21, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- BDTX
- Exchange
- Nasdaq
- IPO date
- Jan 30, 2020
- Shares outstanding
- 57M, Jul 30, 2026
- Public float
- $113.75M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1701541
- CUSIP
- 09203E105
- ISIN
- US09203E1055
- FIGI
- BBG00MS4Y0W9
- Share class FIGI
- BBG00MS4Y0X8
- EIN
- 81-4254660
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark A. Velleca | PRESIDENT & CEO, Director | 121,522 |
| Brent Hatzis-Schoch | SEE REMARKS | 83,400 |
| Sergey Yurasov | CHIEF MEDICAL OFFICER | 75,000 |
| Erika Jones | SEE REMARKS | 85,150 |
| Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | 170,192 |
| Ali Behbahani | Director | 4,558,993 |
| Prakash Raman | Director | 51,840 |
| Kapil Dhingra | Director | 10,000 |
| Samarth Kulkarni | Director | – |
| Garry E. Menzel | Director | 76,644 |
| Shannon Campbell | Director | 8,865 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.23M | $2.57M | $1.32M | $89 | – |
| FY2024 | $2.86M | $1.95M | $1.46M | $76 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Mark A. Velleca, M.D., Ph.D. President and Chief Executive Officer | $667.40K | $189.00K | $1.01M | $348.72K | $23.77K | $2.23M | -22% |
| Brent Hatzis-Schoch, Esq. Chief Operating Officer and General Counsel | $511.00K | $189.00K | $352.03K | $206.44K | $23.77K | $1.28M | -9% |
| Sergey Yurasov, M.D., Ph.D. Chief Medical Officer | $525.60K | $189.00K | $402.35K | $212.34K | $22.81K | $1.35M | -11% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 30, 2020
- Offer price
- $19.00
- Securities offered
- 10,586,316
- Gross proceeds
- $201.14M
- Exchange
- Nasdaq
- First trading day
- Jan 30, 2020
- First-day close
- $39.48+107.8%
- Lock-up ends (est.)
- Jul 28, 2020
“The initial public offering price is $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 11, 2026, we had 21 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 30, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 27, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 4, 2018 | Name change | Name changed from Aset Therapeutics, Inc. to Black Diamond Therapeutics, Inc. |
See a number that looks wrong?